← Atlas Theme · spans 1 topics
America's obesity curve now bends to prescription volume.
With 11% of US adults on GLP-1 therapy, the adult obesity rate has posted its first recorded population-level reversal — 39.9% to 36.8% — making prescription volume, not lifestyle intervention, the operative force in national metabolic statistics.
1
Topics it spans
2
Findings citing it
—
Evidence window
The convergence
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
GLP-1 Cross-Sector Effects
US Adult Obesity Rate Falls to 36.8% as GLP-1 Use Hits 11% — First Population-Level Reversal on Record The first population-level reversal on record arrives in direct lockstep with GLP-1 adoption reaching 11% of adults.
GLP-1 Cross-Sector Effects
GLP-1 Research Cycle Summary — May 28, 2026 A 304-million-record dataset ties the obesity rate's first decline, 42.3% to 40.7%, directly to a quadrupling of prescription volume.